Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis

BACKGROUND AND OBJECTIVES: Rates of malignant melanoma are continuing to increase, and until recently effective treatments were lacking. However, since 2011 three immunotherapeutic agents, known as checkpoint inhibitors, have been approved. This review aims to establish whether these three drugs – i...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlsson, Adam K, Saleh, Sohag N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580705/
https://www.ncbi.nlm.nih.gov/pubmed/28883738
http://dx.doi.org/10.2147/CCID.S120877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580705/
https://www.ncbi.nlm.nih.gov/pubmed/28883738
http://dx.doi.org/10.2147/CCID.S120877

Ejemplares similares